Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Free Cash Flow: 2016-2025

Historic Free Cash Flow for Anaptysbio (ANAB) over the last 10 years, with Sep 2025 value amounting to -$27.4 million.

  • Anaptysbio's Free Cash Flow fell 170.30% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$145.3 million, marking a year-over-year decrease of 40.56%. This contributed to the annual value of -$135.7 million for FY2024, which is 11.58% down from last year.
  • As of Q3 2025, Anaptysbio's Free Cash Flow stood at -$27.4 million, which was up 32.06% from -$40.3 million recorded in Q2 2025.
  • Anaptysbio's 5-year Free Cash Flow high stood at $8.7 million for Q2 2021, and its period low was -$66.9 million during Q4 2024.
  • Its 3-year average for Free Cash Flow is -$30.5 million, with a median of -$27.4 million in 2025.
  • Its Free Cash Flow has fluctuated over the past 5 years, first spiked by 144.32% in 2021, then crashed by 377.55% in 2022.
  • Quarterly analysis of 5 years shows Anaptysbio's Free Cash Flow stood at -$25.3 million in 2021, then spiked by 57.10% to -$10.9 million in 2022, then tumbled by 218.87% to -$34.6 million in 2023, then crashed by 93.29% to -$66.9 million in 2024, then plummeted by 170.30% to -$27.4 million in 2025.
  • Its Free Cash Flow stands at -$27.4 million for Q3 2025, versus -$40.3 million for Q2 2025 and -$10.7 million for Q1 2025.